FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (24)
2023
-
Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD
Respiratory Research, Vol. 24, Núm. 1
-
Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811
-
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
The Lancet Child and Adolescent Health, Vol. 7, Núm. 3, pp. 180-189
-
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 8, pp. 477-480
-
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1759-1770.e7
-
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
Future oncology (London, England), Vol. 19, Núm. 35, pp. 2349-2359
2022
-
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Clinical Cancer Research, Vol. 28, Núm. 20, pp. 4536-4550
-
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
New England Journal of Medicine
-
The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study
Respiratory Medicine, Vol. 200
-
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
New England Journal of Medicine, Vol. 386, Núm. 12, pp. 1142-1154
-
Treatable traits in the NOVELTY study
Respirology, Vol. 27, Núm. 11, pp. 929-940
2021
-
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
npj Breast Cancer, Vol. 7, Núm. 1
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial
Journal of Clinical Oncology
-
Combined MEK and PI3K/p110β inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features
Cancer Research, Vol. 80, Núm. 4, pp. 843-856
-
Reimagining global oncology clinical trials for the postpandemic era: A call to arms
JCO Global Oncology, pp. 1357-1362
2019
-
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
JAMA Oncology, Vol. 5, Núm. 11, pp. 1556-1563
-
Meta-Analysis Design and Results in Real Life: Problem Solvers or Detour to Maze. A Critical Review of Meta-Analysis of DAPT Randomized Controlled Trials
Cardiovascular Revascularization Medicine, Vol. 20, Núm. 10, pp. 897-906
2018
-
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine, Vol. 10, Núm. 12
-
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210